Open AccessPolycaprolactone for the Correction of Nasolabial Folds: A 24‐Month, Prospective, Randomized, Controlled Clinical Trial
Author(s) -
MoersCarpi Marion Michaela,
Sherwood Sally
Publication year - 2013
Publication title -
dermatologic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.659
H-Index - 125
eISSN - 1524-4725
pISSN - 1076-0512
DOI - 10.1111/dsu.12054
Subject(s) - medicine , patient satisfaction , polycaprolactone , randomized controlled trial , wrinkle , visual analogue scale , surgery , prospective cohort study , dentistry , materials science , gerontology , composite material , polymer
Background In this study, we examined two polycaprolactone ( PCL )‐based dermal filler formulas ( PCL ‐1; PCL ‐2) for safety, patient satisfaction, likelihood to return, efficacy, and duration of correction. Objective This 40‐patient, 24‐month, prospective, randomized, controlled study evaluated the efficacy, safety, longevity, and volume of two PCL formulas for correction of nasolabial folds. Methods Patients enrolled in a medical clinic in Europe received two injections 1 month apart and returned at 3, 6, 9, 12, 15, 18, and 24 months for blinded patient evaluation using accepted aesthetic rating scales. Results At 12 months, the efficacy outcomes on W rinkle S everity R ating S cale ( WSRS ) and G lobal A esthetic I mprovement S cale ( GAIS ) of PCL ‐1 and PCL ‐2 were consistently maintained, with sustained improvement in 90% and 91.4% of patients, respectively. At 24 months, PCL ‐2 was found to be more effective than PCL ‐1 with respect to GAIS and WSRS , showing sustained improvement for the entire 2‐year study period (linear p = .52; quadratic p > .99). Patient satisfaction at 24 months was 72.4% for PCL ‐1 and 81.7% for PCL ‐2. Both products were found to be safe and well tolerated. Conclusions PCL ‐1 and PCL ‐2 are safe and have sustained efficacy and high patient satisfaction, with PCL ‐2 demonstrating longer‐lasting results than PCL ‐1.